Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 12/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30044401 | 0.93 | PKMYT1 (0.51) | PKMYT1JAK3EGFRALKSLC2A1 | |
| SCHEMBL23606377 | 0.93 | PKMYT1 (0.51) | PKMYT1JAK3EGFRALKSLC2A1 | |
| SCHEMBL30045155 | 0.91 | JAK3 (0.45) | PKMYT1JAK3MAPK3EGFR | |
| SCHEMBL23606386 | 0.91 | JAK3 (0.45) | PKMYT1JAK3MAPK3EGFR | |
| SCHEMBL23606378 | 0.91 | PLK1 (0.50) | JAK3MAPK3EGFRALK | |
| SCHEMBL30044353 | 0.91 | PLK1 (0.50) | JAK3MAPK3EGFRALK | |
| SCHEMBL25139867 | 0.90 | PLK1 (0.49) | JAK3MAPK3EGFRALK | |
| SCHEMBL30044157 | 0.89 | PLK1 (0.50) | MAPK3EGFR | |
| SCHEMBL25140005 | 0.89 | PLK1 (0.50) | MAPK3EGFR | |
| SCHEMBL25139843 | 0.87 | ALK (0.50) | PKMYT1JAK3MAPK3EGFRALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | FGFR4, FGFR1, WEE1 | PKMYT1 326/4885JAK3 372/4885MAPK3 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.